About Us

Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer. Celleron’s vision is that the future of cancer therapy lies in the ability to match patients to treatments that are tailored to their tumours – effectively selecting the right drug, at the right dose, for the right patient.

Celleron is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. The Company’s lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified.

Celleron’s clinical products, CXD101 and CXD201 in Phase II clinical trials, reflect the Company’s deep scientific understanding of epigenetics, cancer biology, and extensive experience clinical trials of novel cancer agents.

Executive team

Nick-La-Thangue-78920

Professor Nick La Thangue

Chief Executive Officer

Nick has extensive experience of cancer drug development and has founded several companies, including Prolifix and Celleron Therapeutics and more recently Oxford Cancer Biomarkers. He has extensive commercial experience in the biotechnology and pharmaceutical sectors.

He is a fellow of the Royal Society of Edinburgh, a member of the European Molecular Biology Organisation (EMBO), A Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick is Chair of Cancer Biology at the University of Oxford.

Professor David Kerr CBE

Chief Medical Officer

David has an international reputation for the treatment of and research into colorectal cancer and his work has been awarded with several international prizes He is Professor of Cancer Medicine, University of Oxford, and Honorary Professor at Weill-Cornell College of Medicine, New York; 2nd Military University of Shanghai; Xiamen University, China; Seoul National University, Korea. He is a Fellow of the Royal Colleges of Physicians (London, Glasgow and Edinburgh), an Honorary Fellow of the Royal College of General Practitioners, a Founding Fellow of European Academy of Cancer Sciences, Past President of the European Society of Medical Oncology(2009-11) and Fellow of the Academy of Medical Sciences.

Prof-David-Kerr
John-Whittaker

Dr John Whittaker

Chief Operating Officer

John has over 30 years experience in cancer drug development and clinical research. He was previously UK General Manager and Country Manager, Israel, at Kendle International and Director Global Clinical Development. Prior to that, he was Director, Clinical Operations (Europe) for SEQUUS Pharmaceuticals and ALZA International and Director of Oncology, at ICON Clinical Research. His PhD was in genetic toxicology and he was a post-doctoral research fellow at the Sir William Dunn School of Pathology, Oxford University. He has an MBA and has held senior positions with a number of Pharmaceutical and Clinical Research Organisations.

Bill Fleming

Chief Financial Officer

Bill’s career spans over 25 years in a broad range of finance positions. Holding a law degree from Cambridge University and as a qualified ACMA, Bill has accumulated international FD/CFO experience in small venture-backed companies and large blue chips.
Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics, subsequently holding senior finance positions for Bayer Healthcare in Europe and the USA. Bill played a leading role in securing investment for Oxford University spinout Oxitec and in its successful acquisition by Intrexon Corporation.

Bill-Flemming
Collette-Coll

Collette Coll MBA

Operations Director

Collette is a highly qualified and experienced business leader. She has held several management positions in both industry and academia throughout her career. In particular she has several years of recent experience in knowledge and technology transfer developing and delivering a variety of academic and industry partnership programmes across multiple sectors.

Board

Professor Declan Doogan

Chairman

Declan has 30 years experience in drug development and has worked with a number of new drug development companies. He was the Global Head of Development at Pfizer until he retired from that role in 2007. Since then Declan has been President of R&D and then CEO at Amarin. He is currently the CEO of Portage Biotech, a portfolio company developing new drugs using novel protein transporters and the Chair of Biohaven, a spin out from Yale that specialises in psychiatric diseases. He has held a number of visiting professorships at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo), where he has been involved with development of strategies to enhance efficiency of the R&D process.

Prof-Declan-Doogan
Nick-La-Thangue-78920

Professor Nick La Thangue

Chief Executive Officer

Nick has extensive experience of cancer drug development and has founded several companies, including Prolifix and Celleron Therapeutics and more recently Oxford Cancer Biomarkers. He has extensive commercial experience in the biotechnology and pharmaceutical sectors.

He is a fellow of the Royal Society of Edinburgh, a member of the European Molecular Biology Organisation (EMBO), A Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick is Chair of Cancer Biology at the University of Oxford.

Professor David Kerr CBE

Chief Medical Officer

David has an international reputation for the treatment of and research into colorectal cancer and his work has been awarded with several international prizes He is Professor of Cancer Medicine, University of Oxford, and Honorary Professor at Weill-Cornell College of Medicine, New York; 2nd Military University of Shanghai; Xiamen University, China; Seoul National University, Korea. He is a Fellow of the Royal Colleges of Physicians (London, Glasgow and Edinburgh), an Honorary Fellow of the Royal College of General Practitioners, a Founding Fellow of European Academy of Cancer Sciences, Past President of the European Society of Medical Oncology(2009-11) and Fellow of the Academy of Medical Sciences.

Prof-David-Kerr
Prof-Douglas-Marion

Professor Douglas Manion

Director

Doug has 20 years experience in drug development. He was the Senior Vice President, Head of Specialty Development and Head of Japan and China R&D at BMS until October 2016.  He had leadership roles at BMS overseeing various therapeutic areas including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GSK. He started his career at DuPont Pharmaceuticals in 1997.  He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa Canada and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School.

Sangwoo Lee

Director

Sangwoo is the Director of Korean Investment Partner’s US offices, based in Silicon Valley, with worldwide experience in development of investment portfolios. Sangwoo has 18 years industry experience, prior to this, both in corporate and new venture environments, including roles with Samsung Electronics, Dasan Networks, Neomtel and Polidigm.

Ji Woong Chun

Director

Ji Woong is a Healthcare Venture Investment Team Leader in KTB Network, and on the Board of Directors of several biotech companies. Previously, he was in Daiichi Sankyo as a Global Clinical Study Manager. He has a Masters Degree from Seoul National University, and a Pharmacy Degree from Kyung Sung University.

Dr Chris Towler

Chris Towler was educated in the life sciences, gaining a PhD in Biochemistry and undertaking a number of years of post-doctoral research in the area of onco-foetal antigens. He then spent 23
years in the Pharmaceutical Industry (Glaxo and GlaxoWellcome), 13 of which were as leader of a project management organisation within the Development Directorate, followed by a period as head of International and Manufacturing Regulatory Affairs. Chris led the development teams responsible for bringing a number of major novel therapies (including Imigran, Zofran and Relenza) to the market, served as a member of the Corporate Strategy Team and was closely involved with organisational change and post-merger integration projects.

Strategic Collaborations

Celleron has established a unique partnership with Oxford University Hospitals NHS Trust to facilitate its clinical trial programme.

Celleron and AstraZeneca entered into an exclusive world-wide licensing partnership to develop CXD101

Celleron and Nuance Biotech secured a partnership to develop Celleron’s clinical assets in Greater China and South Africa

Business people shaking hands together

Syneous Health™

Combines world-renowned clinical research and commercialization capabilities with today’s most advanced science, business and data technologies to make real advances possible. We help you improve performance, reduce risk and expedite delivery of healthcare innovation to patients worldwide.

Oxford University

The Department of Pharmacology is at the forefront of research into the effects of drugs and other molecules on biological systems with a view to understanding the mechanisms of the human body. Pre-clinical research in the Department aims to examine cellular and molecular pathways in living systems as the first step towards a greater understanding of disease and effective treatment.

Astra Zeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Nuance Biotech

Nuance Biotech is start up biotech company headquartered in Shanghai with a development hub in China and South Africa. It has been founded by a number of globally experienced people with a strong track in China and and beyond.
The company has been established with the view to becoming a leading specialty based player in China through securing and developing novel assets for the China market. Unique to Nuance will be ability to leverage the drug development benefits of China and South Africa for use in both China and the developed markets.
The company has established a platform to compete for commercial, regulatory and development stage assets.

KTB Network

KTB is a professional venture investment company that seeks innovative and creative growth of the business with the most competent investment specialists group from various sectors. Looking for opportunities in all market segments. But over the years we have accrued experience and expertise in finding new opportunities in consumer service, medical/healthcare, education, digital media, entertainment and internet/mobile sectors.

We are recruiting!